Alambic Investment Management L.P. cut its stake in InfuSystem Holdings Inc (NYSEAMERICAN:INFU) by 6.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,184 shares of the medical instruments supplier’s stock after selling 1,100 shares during the period. Alambic Investment Management L.P.’s holdings in InfuSystem were worth $137,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its position in InfuSystem by 13.0% during the 4th quarter. Renaissance Technologies LLC now owns 377,503 shares of the medical instruments supplier’s stock worth $3,220,000 after buying an additional 43,550 shares in the last quarter. Parkman Healthcare Partners LLC bought a new position in shares of InfuSystem in the fourth quarter worth about $1,066,000. EAM Investors LLC acquired a new position in shares of InfuSystem during the fourth quarter worth approximately $914,000. Punch & Associates Investment Management Inc. grew its stake in shares of InfuSystem by 1.9% during the fourth quarter. Punch & Associates Investment Management Inc. now owns 80,500 shares of the medical instruments supplier’s stock valued at $687,000 after purchasing an additional 1,500 shares during the last quarter. Finally, FMR LLC bought a new stake in shares of InfuSystem during the fourth quarter valued at approximately $675,000.
INFU stock traded down $0.15 during trading on Friday, hitting $11.37. The company had a trading volume of 42,219 shares, compared to its average volume of 84,704. InfuSystem Holdings Inc has a 12 month low of $4.20 and a 12 month high of $13.25.
In related news, Director Scott Shuda sold 169,960 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $8.37, for a total transaction of $1,422,565.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul Andrew Gendron acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was acquired at an average price of $5.77 per share, for a total transaction of $57,700.00. Following the completion of the acquisition, the director now directly owns 22,000 shares of the company’s stock, valued at $126,940. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 11,345 shares of company stock worth $69,076.
InfuSystem Holdings Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Featured Story: What is FinTech?
Want to see what other hedge funds are holding INFU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InfuSystem Holdings Inc (NYSEAMERICAN:INFU).
Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.